Zogenix (Zogenix) Net Margin % : -206.27% (As of Dec. 2021)

View and export this data going back to 2010. Start your Free Trial

What is Zogenix Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Zogenix's Net Income for the three months ended in Dec. 2021 was $-54.88 Mil. Zogenix's Revenue for the three months ended in Dec. 2021 was $26.61 Mil. Therefore, Zogenix's net margin for the quarter that ended in Dec. 2021 was -206.27%.

The historical rank and industry rank for Zogenix's Net Margin % or its related term are showing as below:

ZGNX' s Net Margin % Range Over the Past 10 Years
Min: -11499.53 Med: -244.93 Max: 96.18
Current: -278.38

ZGNX's Net Margin % is not ranked
in the Biotechnology industry.
Industry Median: -157.22 vs ZGNX: -278.38

Zogenix Net Margin % Historical Data

The historical data trend for Zogenix's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zogenix Net Margin % Chart

Zogenix Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Margin %

Get a 7-Day Free Trial

-1,291.28

-11,499.53

-1,534.73

-278.39

Zogenix Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Net Margin %	Get a 7-Day Free Trial															-825.34	-406.53	-313.46	-256.54	-206.27

Competitive Comparison of Zogenix's Net Margin %

For the Biotechnology subindustry, Zogenix's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zogenix's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zogenix's Net Margin % distribution charts can be found below:

* The bar in red indicates where Zogenix's Net Margin % falls into.

Zogenix Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Zogenix's Net Margin for the fiscal year that ended in Dec. 2021 is calculated as

Net Margin	=	Net Income (A: Dec. 2021 )	/	Revenue (A: Dec. 2021 )
	=	-227.413	/	81.69
	=	-278.39 %

Zogenix's Net Margin for the quarter that ended in Dec. 2021 is calculated as

Net Margin	=	Net Income (Q: Dec. 2021 )	/	Revenue (Q: Dec. 2021 )
	=	-54.883	/	26.608
	=	-206.27 %

Zogenix (NAS:ZGNX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Zogenix Net Margin % Related Terms

Thank you for viewing the detailed overview of Zogenix's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zogenix (Zogenix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zogenix Inc (NAS:ZGNX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, Suite 500, Emeryville, CA, USA, 94608

Website

https://www.zogenix.com

Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.

Executives

Erle T Mast	director	C/O SPIROS DEVELOPMENT CORP II INC, 7475 LUSK BLVD, SAN DIEGO CA 92121
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Cam L Garner	director	PO BOX 675866, RANCHO SANTE FE CA 92067
Caroline M Loewy	director	300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Denelle J Waynick	director	C/O MYOKARDIA, INC. 1000 SIERRA POINT PARKWAY BRISBANE CA 94005
Mary E. Stutts	director	C/O ZOGENIX, INC. 5959 HORTON STREET EMERYVILLE CA 94608
Ashish M Sagrolikar	officer: EVP & CHIEF COMMERCIAL OFFICER	C/O ZOGENIX, INC. 5858 HORTON STREET, #455 EMERYVILLE CA 94608
Gail M Farfel	officer: EVP/Chief Development Officer	142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Bradley S. Galer	officer: EVP/Chief Medical Officer	C/O ZOGENIX, INC. 12400 HIGH BLUFF DR., SUITE 650 SAN DIEGO CA 92130
Stephen J Farr	director, officer: President and CEO	[email protected] EMERYVILLE CA 94608
Mark C Wiggins	director	12671 HIGH BLUFF DRIVE SUITE 200, SAN DIEGO CA 92130
Louis C Bock	director	C/O BANKAMERICA VENTURES, 950 TOWER LANE STE 700, FOSTER CITY CA 94404
James B Breitmeyer	director
Shawnte Mitchell	officer: EVP, GC and Secretary	5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael P Smith	officer: EVP, CFO, Treasurer & Sec.	887 GREAT NORTHERN WAY VANCOUVER A1 V5T 4T5